Literature DB >> 8581516

Production of PAF-acether by synovial fluid neutrophils in rheumatoid arthritis.

P Hilliquin1, A Dulioust, C Gregoir, A Arnoux, C J Menkés.   

Abstract

PAF-acether (PAF) is a pro-inflammatory phospholipid molecule potentially involved in the pathogenesis of arthritis. PAF and related metabolites have been isolated in the synovial fluid from patients with arthritis. The aim of this study was to determine fluid and blood in patients with rheumatoid arthritis. Blood neutrophils from normal donors were also studied for their capacity to form PAF. Neutrophils were stimulated with the calcium ionophore A23187 (2 microM) for 1 to 60 min. PAF released in the medium and PAF associated to cells were measured. In synovial fluid neutrophils. PAF production began as soon as 1 min of stimulation (16.1 +/- 6.3 pmol per 1 x 10(6) cells) and reached a maximum at 20 min: 29.2 +/- 2.8 pmol per 1 x 10(6) cells (mean +/- SEM, n = 5). The amount of PAF released in the supernatant increased with the length of stimulation, similar amounts of PAF were produced by blood neutrophils isolated from the joint had a lower capacity to produce PAF than blood neutrophils from the same patients. The present results demonstrate the synthesis and release of PAF by synovial fluid neutrophils. They suggest that neutrophils may be source of PAF locally present in the joint. Newly synthesized PAF could participate in the amplification of the local inflammatory reaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581516     DOI: 10.1007/bf01796260

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  15 in total

1.  Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.

Authors:  A Dulioust; P Hilliquin; C J Menkes; J Benveniste; B Arnoux
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

2.  Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.

Authors:  D Nunez; M Chignard; R Korth; J P Le Couedic; X Norel; B Spinnewyn; P Braquet; J Benveniste
Journal:  Eur J Pharmacol       Date:  1986-04-16       Impact factor: 4.432

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Platelet-activating factor production in human neutrophils by sequential stimulation with granulocyte-macrophage colony-stimulating factor and the chemotactic factors C5A or formyl-methionyl-leucyl-phenylalanine.

Authors:  U Wirthmueller; A L De Weck; C A Dahinden
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

5.  Biosynthesis of paf-acether. Paf-acether but not leukotriene C4 production is impaired in cultured macrophages.

Authors:  A Dulioust; E Vivier; N Meslier; R Roubin; I Haye-Legrand; J Benveniste
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

6.  Presence of paf-acether in rheumatic diseases.

Authors:  P Hilliquin; C J Menkes; S Laoussadi; J Benveniste; B Arnoux
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

7.  Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation.

Authors:  G Camussi; C Tetta; F Bussolino; F Caligaris Cappio; R Coda; C Masera; G Segoloni
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

8.  1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes.

Authors:  F H Chilton; J M Ellis; S C Olson; R L Wykle
Journal:  J Biol Chem       Date:  1984-10-10       Impact factor: 5.157

9.  The release of platelet-activating factor from human endothelial cells in culture.

Authors:  G Camussi; M Aglietta; F Malavasi; C Tetta; W Piacibello; F Sanavio; F Bussolino
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

10.  Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes.

Authors:  E Jouvin-Marche; E Ninio; G Beaurain; M Tence; P Niaudet; J Benveniste
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

View more
  2 in total

1.  The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia.

Authors:  Ana T Guerrero; Ana C Zarpelon; Ana C Zaperlon; Silvio M Vieira; Larissa G Pinto; Sérgio H Ferreira; Fernando Q Cunha; Waldiceu A Verri; Thiago M Cunha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-11-28       Impact factor: 3.000

2.  Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Authors:  Anna Södergren; Kjell Karp; Christine Bengtsson; Bozena Möller; Solbritt Rantapää-Dahlqvist; Solveig Wållberg-Jonsson
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.